Boehringer Ingelheim’s obesity asset survodutide, which it licensed from Zealand Pharma, has shown high rates of discontinuations in its Phase 3 obesity study. In April, data from the SYNCHRONIZE-1 trial conducted in patients with obesity ...

開く

最新アーカイブ

FierceBiotech 2026年6月7日

ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect

FierceBiotech 2026年6月6日

ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes

Clinical OMICs 2026年6月6日

GLP-1 Drugs Lower Risk of Death by 44% in Obesity and Autoimmune Disease

Cell 2026年6月6日

Deep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvation

Cell 2026年6月6日

Replaying germinal center evolution on a quantified affinity landscape

Cell 2026年6月6日

Xenophagocytosis blockade enhances interspecies chimerism

FierceBiotech 2026年6月6日

ADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buy

FierceBiotech 2026年6月6日

‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs

Brady Corporation 2026年6月6日

Label Maker Market Forecast Points Higher Toward 2035, Driven by Commercial Micro-Enterprise Demand - IndexBox

Amgen 2026年6月6日

Amgen: A Biotech Giant's Path to Recovery and Growth - AOL.com

Amgen 2026年6月6日

Amgen: A Biotech Giant's Path to Recovery and Growth - The Motley Fool

Novo Nordisk 2026年6月5日

Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026 - PR Newswire

Endpoints News 2026年6月5日

#ADA26: Roche incretin shot works in mid-stage trial in type 1 diabetes

Novo Nordisk 2026年6月5日

Veru (NASDAQ: VERU) Stock Price Surges Over 160% After Clinical Supply Deal With Novo Nordisk (NYSE: NVO) - foreignpolicyjournal.com

Recursion 2026年6月5日

Recursion Pharma director Christopher Gibson sells $144,800 in stock - Investing.com

Intuitive Surgical 2026年6月5日

What's Powering Intuitive Surgical's Market Momentum? - Kalkine Media

MACHEREY-NAGEL GmbH & Co. KG 2026年6月5日

Transfer Membranes for Blotting Market Forecast Points Higher Toward 2035, Driven by Biopharma QC Expansion - IndexBox

Clinical OMICs 2026年6月5日

Blood-Based Risk Score Could Enable Earlier Lung Cancer Prevention